Amended Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k/a)
October 13 2020 - 9:17AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K/A
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of: August 2020
Commission file number: 001-36578
ENLIVEX THERAPEUTICS LTD.
(Translation of registrant’s name
into English)
14 Einstein Street, Nes Ziona, Israel
7403618
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐
This Amendment
to the Report on Form 6-K for the month of August 2020, originally by Enlivex Therapeutics Ltd., a company organized under the
laws of the State of Israel (“Enlivex”), with the Securities and Exchange Commission on August 14, 2020
(the “Form 6-K”), is being filed solely for the purposes of furnishing the Interactive Data File disclosure
as Exhibit 101 in accordance with Rule 405 of Regulation S-T.
Other than as
expressly set forth above, this Report on Form 6-K/A does not, and does not purport to, amend, update or restate the information
in any other item of the Form 6-K, or reflect any events that have occurred after the Form 6-K was originally filed.
This
Report on Form 6-K/A, including the exhibits hereto, is incorporated by reference into Enlivex’s registration statements on
Form F-3 (File No. 333-232413 and File No. 333-232009) filed with the Securities and Exchange Commission.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Enlivex Therapeutics Ltd.
|
|
(Registrant)
|
|
|
|
By:
|
/s/ Oren Hershkovitz
|
|
Name:
Title:
|
Oren Hershkovitz
Chief Executive Officer
|
Date: October 13, 2020
2
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Sep 2023 to Sep 2024